1. Guenther, A, Krauss, E, Tello, S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res 2018; 19: 141. DOI: 10.1186/s12931-018-0845-5.
Google Scholar | Crossref | Medline2. Hammond, M, Clark, AB, Cahn, AP, et al. The efficacy and mechanism evaluation of treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. Trials 2018; 19: 89. DOI: 10.1186/s13063-018-2453-6.
Google Scholar | Crossref | Medline3. Jones, PW, Quirk, FH, Baveystock, CM, et al. A self-complete measure of health status for chronic airflow limitation: the St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321–1327. DOI: 10.1164/ajrccm/145.6.1321.
Google Scholar | Crossref | Medline | ISI4. Patel, AS, Siegert, RJ, Brignall, K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012; 67: 804–810. Research Support, Non-U.S. Gov't Validation Studies. 2012/05/05. DOI: 10.1136/thoraxjnl-2012-201581.
Google Scholar | Crossref | Medline | ISI5. Alma, H, de Jong, C, Jelusic, D, et al. Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference. NPJ Prim Care Respir Med 2016; 26: 16041. 2016/09/07. DOI: 10.1038/npjpcrm.2016.41.
Google Scholar | Crossref | Medline6. Yorke, J, Jones, PW, Swigris, JJ, et al. Development and validity testing of an IPF-specific version of the St George’s Respiratory Questionnaire. Thorax: Multicenter Study Randomized Controlled Trial Research Support 2010; 65: 921–926. N.H.I., Extramural Research Support. Non-U.S. Govt Validation Studies. 2010/09/24. DOI: 10.1136/thx.2010.139121.
Google Scholar | Crossref7. Eakin, EG, Resnikoff, PM, Prewitt, LM, et al. Validation of a new dyspnea measure: the UCSD shortness of breath questionnaire. Chest 1998; 113: 619–624.Research Support, Non-U.S. Gov't Research Support, U.S. Govt, P.H.S. 1998/03/27.
Google Scholar | Crossref | Medline | ISI8. Papiris, SA, Daniil, ZD, Malagari, K, et al. Τhe medical research council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005; 99: 755–761, DOI: 10.1016/j.rmed.2004.10.018.
Google Scholar | Crossref | Medline | ISI9. Herdman, M, Gudex, C, Lloyd, A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727–1736. DOI: 10.1007/s11136-011-9903-x.
Google Scholar | Crossref | Medline | ISI10. Antoniou, K, Kamekis, A, Symvoulakis, EK, et al. Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review. Curr Opin Pulm Med 2020; 26: 457–463. DOI: 10.1097/MCP.0000000000000703.
Google Scholar | Crossref | Medline11. Swigris, JJ, Esser, D, Conoscenti, CS, et al. The psychometric properties of the St George’s Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes 2014; 12: 124. DOI: 10.1186/s12955-014-0124-1.
Google Scholar | Crossref | Medline | ISI12. Swigris, JJ, Esser, D, Wilson, H, et al. Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis. Eur Respir J 2017; 49: 1601788. DOI: 10.1183/13993003.01788-2016.
Google Scholar | Crossref | Medline13. Swigris, JJ, Wilson, H, Esser, D, et al. Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials. BMJ Open Respir Res 2018; 5: e000278. DOI: 10.1136/bmjresp-2018-000278.
Google Scholar | Crossref | Medline14. Prior, TS, Hilberg, O, Shaker, SB, et al. Validation of the king’s brief interstitial lung disease questionnaire in idiopathic pulmonary fibrosis. BMC Pulm Med 2019; 19: 255–2019. DOI: 10.1186/s12890-019-1018-0.
Google Scholar | Crossref | Medline15. Prior, TS, Hoyer, N, Shaker, SB, et al. Validation of the IPF-specific version of St. George's Respiratory Questionnaire. Respir Res 2019; 20: 199. DOI: 10.1186/s12931-019-1169-9.
Google Scholar | Crossref | Medline16. Raghu, G, Collard, HR, Egan, JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824. 2011/04/08. DOI: 10.1164/rccm.2009-040GL.
Google Scholar | Crossref | Medline | ISI17. King, TE, Behr, J, Brown, KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75–81. 2007/09/29. DOI: 10.1164/rccm.200705-732OC.
Google Scholar | Crossref | Medline | ISI18. Zigmond, AS, Snaith, RP. The hospital anxiety and depression scale. Acta Psychiatrica Scand 1983; 67: 361–370.
Google Scholar | Crossref | Medline | ISI19. Kamper, S. . Global rating of change scales. Aust J Physiother 2009; 55: 289. 2009/11/26. DOI: 10.1016/s0004-9514(09)70015-7.
Google Scholar | Crossref | Medline20. Miller, M. R., Hankinson, J, Brusasco, V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.
Google Scholar | Crossref | Medline | ISI21. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111–117. Guideline Practice Guideline 2002/07/02. DOI: 10.1164/ajrccm.166.1.at1102.
Google Scholar | Crossref | Medline | ISI22. Tavakol, M, Dennick, R. Making sense of cronbach’s alpha. Int J Med Educ 2011; 2: 53–55. 2011/06/27. DOI: 10.5116/ijme.4dfb.8dfd.
Google Scholar | Crossref | Medline23. Szentes, BL, Kreuter, M, Bahmer, T, et al. Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res 2018; 19: 101. DOI: 10.1186/s12931-018-0808-x.
Google Scholar | Crossref | Medline24. Ryerson, CJ, Vittinghoff, E, Ley, B, et al. Predicting Survival Across Chronic Interstitial Lung Disease. Chest 2014; 145: 723–728. 2013/10/12. DOI: 10.1378/chest.13-1474.
Google Scholar | Crossref | Medline25. Revicki, D, Hays, RD, Cella, D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61: 102–109, DOI: 10.1016/j.jclinepi.2007.03.012.
Google Scholar | Crossref | Medline | ISI26. Kamper, SJ, Maher, CG, Mackay, G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manipulative Ther 2009; 17: 163–170. 2010/01/05. DOI: 10.1179/jmt.2009.17.3.163.
Google Scholar | Crossref | Medline27. Kreuter, M, Swigris, J, Pittrow, D, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res 2017; 18: 139. DOI: 10.1186/s12931-017-0621-y.
Google Scholar | Crossref | Medline28. Mouelhi, Y, Jouve, E, Castelli, C, et al. How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods. Health Qual Life Outcomes 2020; 18: 136. DOI: 10.1186/s12955-020-01344-w.
Google Scholar | Crossref | Medline29. Revicki, DA, Cella, D, Hays, RD, et al. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006; 4: 70. DOI: 10.1186/1477-7525-4-70.
Google Scholar | Crossref | Medline | ISI30. Kreuter, M, Wuyts, WA, Wijsenbeek, M, et al. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS trials. Respir Res 2020; 21: 36. DOI: 10.1186/s12931-020-1298-1.
Google Scholar | Crossref | Medline31. Suzuki, A, Kondoh, Y, Swigris, JJ, et al. Performance of the St George’s Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease. Respirology 2018; 23: 851–859. DOI: 10.1111/resp.13293.
Google Scholar | Crossref32. Sinha, A, Patel, AS, Siegert, RJ, et al. The king’s brief interstitial lung disease (KBILD) questionnaire: an updated minimal clinically important difference. BMJ Open Respir Res 2019; 6: e000363. DOI: 10.1136/bmjresp-2018-000363.
Google Scholar | Crossref | Medline33. Nolan, CM, Birring, SS, Maddocks, M, et al. King’s brief interstitial lung disease questionnaire: responsiveness and minimum clinically important difference. Eur Respir J 2019; 54: 1900281. DOI: 10.1183/13993003.00281-2019.
Google Scholar | Crossref | Medline34. Prior, TS, Hoyer, N, Hilberg, O, et al. Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis. Respir Res 2020; 21: 91. 2020/04/23. DOI: 10.1186/s12931-020-01359-3.
Google Scholar | Crossref | Medline35. Case, AH, Hellkamp, AS, Neely, ML, et al. Associations between patient-reported outcomes and death or lung transplant in IPF: data from the IPF-PRO Registry. Ann Am Thorac Soc 2020; 17(6): 699–705. DOI: 10.1513/AnnalsATS.201906-437OC.
Google Scholar | Crossref | Medline36. Sharp, C, Baggott, C, Birring, S, et al. S20 Kbild scores have similar power to predict survival as pulmonary physiology in interstitial lung disease. Thorax 2016; 71: 2–A14. DOI: 10.1136/thoraxjnl-2016-209333.26.
Google Scholar | Crossref37. Ryerson, CJ, Berkeley, J, Carrieri-Kohlman, VL, et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011; 139: 609–616. 2010/08/07. DOI: 10.1378/chest.10-0608.
Google Scholar | Crossref | Medline | ISI38. Holland, AE, Fiore, JF, Bell, EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology 2014; 19: 1215–1221. DOI: 10.1111/resp.12360.
Google Scholar | Crossref | Medline | ISI39. Lee, YJ, Choi, SM, Lee, YJ, et al. Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis. PloS one 2017; 12: e0184300. 2017/09/12. DOI: 10.1371/journal.pone.0184300.
Google Scholar | Crossref | Medline